Featured Research

from universities, journals, and other organizations

Anti-Cocaine Vaccine Produces Antibodies, Shown To Be Safe In Yale Researcher's Phase 1 Study

Date:
March 10, 2000
Source:
Yale University
Summary:
A therapeutic cocaine vaccine designed to suppress the high addicts get from taking cocaine is safe and produced cocaine antibodies in humans, a Yale study finds.

New Haven, Conn. -- A therapeutic cocaine vaccine designed to suppress the high addicts get from taking cocaine is safe and produced cocaine antibodies in humans, a Yale study finds.

Thomas Kosten, M.D., principal investigator on the phase 1 study, and his team administered the vaccine to 34 former cocaine abusers living in a residential treatment facility.

The vaccine, TA-CD, is designed to generate drug-specific antibodies, which bind to cocaine and prevent it from traveling to the brain from the bloodstream. This neutralizes its psychoactive effect.

"The vaccine is very safe and we did not observe any major side effects," said Kosten, professor of psychiatry at Yale School of Medicine. "TA-CD was effective in producing cocaine-specific antibodies, which lasted throughout the trial. More advanced trials are already underway. TA-CD offers the potential for a completely new and highly viable approach to a very serious problem for which there are no alternative therapies available."

Such a product, Kosten said, would be complementary to behavioral therapy in overcoming cocaine addiction. This vaccine would target the more than two million regular cocaine users in the United States alone. Of these, 900,000 seek treatment each year.

In the Phase 1 trial, the vaccine was given to 34 subjects split into three cohorts to evaluate three different doses of the vaccine following 30 days of abstinence. Two subjects in each cohort

received a placebo and the rest received active vaccine. The study's participants had to meet the criteria for cocaine dependence, including a three- to 10-year cocaine habit, and willingness to get treatment and participate in the study.

The people in the study, Kosten said, had a motivation to want to stop using cocaine. This desire to stop is the key factor of any successful treatment outcome.

The vaccine does not take away the desire or the craving for cocaine, Kosten said, but the antibodies it generates block the priming effect and the reinforcement of the craving, if a recovering addict takes cocaine after giving up the drug. To override the vaccine's effects, it may be possible to take massive amounts of cocaine, but it is unlikely that addicts who are actively working to overcome their addiction would want to do that.

Kosten is currently conducting a Phase 11a dose escalation trial involving cocaine addicts in an out-patient treatment program. Once this is complete, a dose will be selected for pivotal efficacy trials, which will aim to evaluate the effect of TA-CD on reducing patient cocaine use.

Cocaine is the second most commonly abused drug after alcohol and the average age of a cocaine user is 42. Most cocaine addicts are treated by physicians or psychiatrists in drug rehabilitation centers. Due to the high relapse rate associated with current therapies, Kosten said, there is a clear need for an effective treatment to be used alongside a behavioral program.

The study was supported by the National Institute on Drug Abuse (NIDA), one of the National Institutes of Health.

TA-CD is being developed by Cantab Pharmaceuticals plc, a Cambridge, England-based biopharmaceutical company.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "Anti-Cocaine Vaccine Produces Antibodies, Shown To Be Safe In Yale Researcher's Phase 1 Study." ScienceDaily. ScienceDaily, 10 March 2000. <www.sciencedaily.com/releases/2000/03/000309075053.htm>.
Yale University. (2000, March 10). Anti-Cocaine Vaccine Produces Antibodies, Shown To Be Safe In Yale Researcher's Phase 1 Study. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2000/03/000309075053.htm
Yale University. "Anti-Cocaine Vaccine Produces Antibodies, Shown To Be Safe In Yale Researcher's Phase 1 Study." ScienceDaily. www.sciencedaily.com/releases/2000/03/000309075053.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins